

## HB 2511 STAFF MEASURE SUMMARY

### House Committee On Health Care

---

**Prepared By:** Oliver Droppers, LPRO Analyst

**Sub-Referral To:** Joint Committee On Ways and Means

**Meeting Dates:** 1/29

---

#### WHAT THE MEASURE DOES:

Requires commercial carriers and state Medicaid to cover treatment costs for patients with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS). Defines PANDAS and PANS. Requires the Oregon Health Authority (OHA) to ensure reimbursement for services related to PANDAS and PANS treatments adhere to existing state Medicaid law including requiring a coordinated care organization to reimburse for the costs of treatment. Requires OHA to create an advisory council to provide education.

*REVENUE: May have revenue impact, but no statement yet issued.*

*FISCAL: May have fiscal impact, but no statement yet issued.*

#### ISSUES DISCUSSED:

#### EFFECT OF AMENDMENT:

No amendment.

#### BACKGROUND:

The National Institute of Mental Health defines pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS) as pediatric disorders that often appear in childhood from age 3 to 12. The diagnosis of PANDAS is a clinical diagnosis based on diagnostic criteria by a health care professional. Symptoms may include motor or vocal tics, obsessions, compulsions, or a combination of these. PANDAS is a diagnosis given to children who experience a sudden and dramatic onset or worsening of Obsessive Compulsive Disorder (OCD) and/or tic disorders following a streptococcal infection. Children diagnosed with PANDAS may also experience anxiety, inattention, trouble sleeping, and changes in motor skills, among other symptoms.

A distinction between PANDAS and PANS is that children diagnosed with PANS have no association with an underlying streptococcal infection. Both PANDAS and PANS are described in the medical literature as episodic conditions, and individuals diagnosed with PANDAS or PANS are expected to experience periods of symptom reduction or remission with the disorders.

House Bill 2511 mandates commercial and Medicaid health coverage for treatment of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS).